STEPHEN KRAMER
Psychiatric at San Felipe St, Houston, TX

6534507, Mar 18, 2003

Nov 13, 2000

09/709741

Stephen J. Kramer - Houston TX
Louis F. Fabre - Houston TX
Edward H. Ruediger - Greefield Park, CA
Joseph P. Yevich - Southington CT

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31506

51425214, 51425218

Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.

2003022, Nov 27, 2003

Feb 7, 2003

10/149962

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US
Edward Ruediger - Greenfield Park, CA
Joseph Yevich - Southington CT, US

A61K031/496

514/252180

Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,dethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.

2008024, Oct 9, 2008

Jun 16, 2008

12/139851

Stephen J. KRAMER - Houston TX, US
Louis F. Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61K 31/437, A61K 9/12

424 43, 514300

The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

2013015, Jun 13, 2013

Dec 10, 2012

13/709986

Stephen J. Kramer - Houston TX, US

Fabre-Kramer Pharmaceuticals.Inc. - Houston TX

A61K 31/506, A61K 45/06

51425218

A method of treatment of depression in a person also taking non-Steroidal anti-inflammatory drugs (NSAIDs) by administering gepirone as either a short term or long term therapy.

2004024, Dec 2, 2004

Mar 17, 2004

10/801856

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61L009/04, A61K031/4745

424/045000, 514/303000

One embodiment of the present invention provides a pharmaceutical composition for nasal administration, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form. Another embodiment of the present invention provides a method for inducing sleep, which includes nasally administering to a subject in need thereof a pharmaceutical composition, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

2013026, Oct 10, 2013

Mar 15, 2013

13/841161

Stephen J. KRAMER - Houston TX, US
Lou SMITH - Houston TX, US

FABRE-KRAMER PHARMACEUTICALS, INC. - Houston TX

A61K 31/506

51425218, 51425214

A method of treating and/or lowering elevated cholesterol by administering a therapeutically effective amount of at least one 5HTreceptor agonist to a subject in need thereof as either a short term or long term therapy. Also, a method of maintaining clinically acceptable cholesterol levels, or cholesterol levels below an elevated amount, by administering a therapeutically effective amount of at least one 5HTreceptor agonist to a subject in need thereof as either a short term or long term therapy.

2005009, May 5, 2005

Jun 25, 2004

10/875384

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceuticals, Inc. - Houston TX

A61K031/506, A61K009/20

424464000, 514252190

A pharmaceutical composition is provided, which includes: at least one active ingredient selected from the group including adatanserin, a compound having formula I, a compound having formula II, abaperidone, pharmaceutically acceptable salt thereof, prodrug thereof, and a mixture thereof; at least one high or medium viscosity hydroxypropylmethylcellulose (HPMC); at least one high or medium viscosity hydroxyethylcellulose (HEC); wherein the HPMC and HEC are present in a HPMC/HEC weight ratio ranging from 1/0.5 to 1/1.5; wherein adatanserin, abaperidone, and the compounds having formulas (I) and (II) are defined herein.

2006009, May 11, 2006

Nov 5, 2004

10/981663

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre-Kramer Pharmaceuticals, Inc. - Houston TX

A61K 31/506, A61K 9/14

424488000, 514252180

The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.

2004000, Jan 1, 2004

Jun 28, 2002

10/183527

Stephen Kramer - Houston TX, US
Louis Fabre - Houston TX, US

Fabre Kramer Pharmaceutical, Inc. - Houston TX

A61K031/506, A61K031/4747

514/252150, 514/278000

The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HTreceptor agonists